Methodological Priorities for Patient Preferences Research: Stakeholder Input to the PREFER Public-Private Project

Note: Funding Information: The PREFER project has received funding from the IMI 2 Joint Undertaking under grant agreement number 115966. This joint undertaking receives support from the EU’s Horizon 2020 Research and Innovation Program and the EFPIA. Funding Information: PREFER is a 5-year project, funded jointly by the Innovative Medicines Initiative (IMI) 2 (EU Horizon 2020) and the European pharmaceutical industry [represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA)]. PREFER aims to strengthen patient-centric decision making throughout the MPLC by developing evidence-based recommendations to fill the gaps in knowledge regarding the methodological aspects of patient preference studies.